Inclusion Criteria

Inclusion Criteria

- patients with histologically proven stage III/IV centroblastic/centrocytic (FL),
centrocytic (MCL)or lymphoplasmacytoid lymphoma (LPIC).

- relapsed disease after initial chemotherapy or peripheral blood stem cell
transplantation

- two-dimensionally measurable lesion outside a previously irradiated area
(osteoblastic bone lesions, ascites, and pleural effusions are not evaluable)

- age > 18 years

- Karnofsky-index > 60

- life expectancy of at least 3 months

- effective contraception in female premenopausal patients

- patient's written informed consent

Exclusion Criteria:

- age < 18 years

- Karnofsky-index < 60

- treatment with fludarabine or mitoxantrone within the preceding three months

- active auto-immune hemolytic anemia at the start of FCM chemotherapy

- participation in another clinical trial during the last 4 weeks

- participation in this study before

- previous treatment with murine antibodies

- concurrent diseases which exclude the administration of therapy as outlined by the
study protocol

- non-compensated heart failure

- dilatative cardiomyopathy

- coronary heart disease with ST segment depression in ECG

- myocardial infarction during the last 6 months

- chronic lung disease with hypoxemia

- severe non-compensated hypertension

- severe non-compensated diabetes mellitus

- renal insufficiency (creatinine > 2.0 mg/dl), not related to lymphoma

- hepatic insufficiency with transaminase values greater than 3-fold of normal values
and/or bilirubin levels > 2.0 mg/dl, not related to lymphoma

- clinical signs of cerebral dysfunction

- women during lactation or pregnancy or of childbearing potential not using a reliable
contraceptive method

- severe psychiatric disease

- serological positivity for HBV, HCV, HIV

- previous organ transplantation other than autologous peripheral blood stem cell
transplantation

- missing written informed consent or missing written consent for data protection